Sysmex (OTCMKTS:SSMXY) Raised to Hold at Zacks Research

Sysmex (OTCMKTS:SSMXY) was upgraded by investment analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report released on Tuesday,Zacks.com reports.

Sysmex Stock Performance

Shares of SSMXY stock opened at $12.12 on Tuesday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.46 and a current ratio of 3.26. The firm has a market cap of $7.63 billion, a P/E ratio of 28.86 and a beta of 1.05. The firm’s 50 day moving average price is $9.85 and its 200-day moving average price is $9.20. Sysmex has a one year low of $8.01 and a one year high of $13.49.

Sysmex (OTCMKTS:SSMXY) last posted its earnings results on Friday, August 7th. The company reported $0.09 earnings per share for the quarter, beating the consensus estimate of $0.07 by $0.02. Sysmex had a net margin of 7.62% and a return on equity of 7.87%. The firm had revenue of $825.85 million during the quarter, compared to the consensus estimate of $741.67 million. Sysmex has set its FY 2026 guidance at 0.382-0.382 EPS. As a group, equities research analysts predict that Sysmex will post 0.38 EPS for the current year.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.